Search results for Specialty Drugs

<![CDATA[Asembia AXS26 Summit: The Future of High-Cost Specialty Drugs ]]>

A look at payers' attitudes toward specialty drug management

Insurers are putting a growing focus on specialty drugs covered under the medical benefit, and on re-evaluating the efficacy of traditional rebate models, according to a new report...

The Top 15 Specialty Pharmacies of 2025: PBM-Affiliated Pharmacies Dominate While Health Systems and Independents Gain G...

By Adam J. Fein, Ph.D.Drug Channels Institute’s (DCI’s) latest analysis reveals that PBM-affiliated specialty pharmacies continue to dominate the dispensing of specialty drugs....

Specialty Pharmacy Accreditation: DCI’s Exclusive Analysis Reveals a Market at an Inflection Point

The Drug Channels Institute (DCI) team attended Asembia’s AXS26 Summit last week. Once again, the specialty pharmacy market delivered a classic paradox: a sprawling, fragmented lan...

Timely by DrFirst Aims to Lower Barriers to Specialty Meds

Timely by DrFirst launched a tool to streamline prior authorizations and improve access to specialty medications. The post Timely by DrFirst Aims to Lower Barriers to Specialty Med...

<![CDATA[Exception Pathways, In-Benefit Optimization: Two Approaches to Specialty Savings]]>

The Top 15 Specialty Pharmacies of 2025: PBM-Affiliated Pharmacies Dominate While Health Systems and Independents Gain G...

The Top 15 Specialty Pharmacies of 2025: PBM-Affiliated Pharmacies Dominate While Health Systems and Independents Gain Ground Anonymous (not verified) Tue, 04/21/2026 - 08:11...

<![CDATA[What's Driving the Concentration of Blockbuster Drugs]]>

Ars Pharmaceuticals anticipates CVS Caremark decision as it expands $199 retail access program

Specialty Pharma Hits 5% Following International Distribution Order Worth $1.5 Million

Synopsis:- Speciality Medicines Limited, listed on BSE-SME just 23 days ago, has announced a commercial distribution arrangement with an unnamed international entity for pharmaceut...

Healthcare & Life Sciences: Drug Pricing Digest - April 2026 #2

Our Drug Pricing and Market Access team tracks recent developments in healthcare reform, the Medicaid Drug Rebate Program, the 340B Program, Medicare, and state law....By: Latham &...

GLP-1s, Specialty Spend, and a 9% Cost Surge: Why Employers Must Rethink Primary Care Now

The question isn’t whether costs will rise. It’s whether employers will continue managing around the margins — or address the root cause. The post GLP-1s, Specialty Spend, and a 9%...

<![CDATA[Top Drugs at Risk of Supply Shortages: Report ]]>

Drug Channels News Roundup, April 2026: PBM Specialty Pharmacy Steering, MLR Profit Shifting, Hospitals’ Fake Prices, an...

Spring has officially arrived at Drug Channels' worldwide headquarters in beautiful downtown Philadelphia. (Photo proof at right.) So, dive into this month’s curated crop of notewo...

Healthcare & Life Sciences: Drug Pricing Digest - March 2026 #2

Our Drug Pricing and Market Access team tracks recent developments in healthcare reform, the Medicaid Drug Rebate Program, the 340B Program, Medicare, and state law....By: Latham &...

Healthcare & Life Sciences: Drug Pricing Digest - May 2026 #2

Our Drug Pricing and Market Access team tracks recent developments in healthcare reform, the Medicaid Drug Rebate Program, the 340B Program, Medicare, and state law....By: Latham &...

Emerging Alternatives for GLP-1 Prescription Drug Coverage: What Plan Sponsors Need to Know

As GLP-1 medications become an increasingly significant cost driver for employer-sponsored health plans, plan sponsors are seeking creative solutions beyond conventional pharmacy b...

<![CDATA[Asembia AXS26: The Battle for Drug Prices Ahead of the Midterms]]>

<![CDATA[Asembia ASX26: Payers and the Rising Costs for Cell & Gene Therapies]]>

The Big Three PBMs’ 2026 Formulary Exclusions: MFP, Private Label Biosimilars, and Direct-to-Patient Threats for PBMs (r...

This week, we're rerunning some popular posts while we prepare for Friday’s live video webinar: PBM Industry Update 2026: Trends, Challenges, and What’s Ahead. Click here to see...

Emcure expands global business, bets on complex drugs pipeline

Overseas sales outpace domestic growth; company scales injectables, biosimilars, expands in Europe, Canada

Coram CVS Specialty shifts to paper-based drug packaging

Coram CVS Specialty Infusion Services has started using a new paper-based packaging for temperature-sensitive medicines. The post Coram CVS Specialty shifts to paper-based drug pac...

Drug Channels News Roundup, Mid-May 2026: Flawed Launch Price Math, Rising Pharmacy Closures, Hospital Pay Realities, 34...

By Bryce Platt, PharmD The onslaught of pharmacy-related news doesn’t end. It may even be increasing in volume due to AI. But don’t worry—I’ve gathered some high-impact inf...

Humana's CenterWell, Mark Cuban Cost Plus Drugs partner to tackle employers' drug costs

The arrangement aims to create new "end-to-end employer prescription solutions" fueled by Cost Plus Drugs' software platform and drug pricing, as well as CenterWell Pharmacy's dist...